Ignite Creation Date:
2025-12-24 @ 4:55 PM
Ignite Modification Date:
2025-12-28 @ 8:52 PM
Study NCT ID:
NCT01229150
Status:
COMPLETED
Last Update Posted:
2017-05-23
First Post:
2010-10-26
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2010-10-26
Start Date Type:
ACTUAL
Primary Completion Date:
2013-09-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2015-11-21
Completion Date Type:
ACTUAL
First Submit Date:
2010-10-26
First Submit QC Date:
None
Study First Post Date:
2010-10-27
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2014-10-23
Results First Submit QC Date:
None
Results First Post Date:
2014-10-29
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-04-17
Last Update Post Date:
2017-05-23
Last Update Post Date Type:
ACTUAL